Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 15/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733331 | 0.84 | PIK3CG (0.41) | PIK3CGPIK3CDPIK3CAKEAP1NFE2L2 | |
| SCHEMBL10456 | 0.84 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CAMAPK1CYP2C9 | |
| SCHEMBL10361 | 0.83 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CACYP2C9 | |
| SCHEMBL10234 | 0.82 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CAKEAP1NFE2L2 | |
| SCHEMBL10434 | 0.79 | PIK3CG (0.45) | PIK3CGPIK3CDPIK3CAMAPK1CYP2C9 | |
| SCHEMBL9990 | 0.79 | PIK3CG (0.68) | PIK3CGPIK3CDPIK3CACYP2C9PRKDC | |
| SCHEMBL10392 | 0.78 | PIK3CG (0.51) | PIK3CGPIK3CDPIK3CACYP2C9PRKDC | |
| SCHEMBL13739 | 0.77 | PIK3CG (0.48) | PIK3CGPIK3CDPIK3CAMAPK1CYP2C9 | |
| SCHEMBL12991905 | 0.76 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3CACYP2C9PRKDC | |
| SCHEMBL12710086 | 0.71 | PIK3CG (0.45) | PIK3CGPIK3CDPIK3CACYP2C9PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041634-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081316-A1 | PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIK3CG | PIK3CG 3/4885PIK3CD 2/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.